Adagio Therapeutics Inc Forecast, price target & analysts
Adagio Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Adagio Therapeutics Inc Classifications & Recommendation:
Adagio Therapeutics Inc Price Target
| Target Price | $4.93 |
| Price | $0.79 |
| Potential |
522.90%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Adagio Therapeutics Inc 2026 .
The average Adagio Therapeutics Inc target price is $4.93.
This is
522.90%
register free of charge
$9.00
1,036.36%
register free of charge
$0.80
1.01%
register free of charge
|
|
| A rating was issued by 3 analysts: 2 Analysts recommend Adagio Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Adagio Therapeutics Inc stock has an average upside potential 2026 of
522.90%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 25.38 | 110.78 |
| 336.50% | ||
| EBITDA Margin | -684.63% | -19.95% |
| 97.09% | ||
| Net Margin | -669.54% | -4.69% |
| 99.30% |
3 Analysts have issued a sales forecast Adagio Therapeutics Inc 2025 . The average Adagio Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Adagio Therapeutics Inc 2025 . The average Adagio Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Adagio Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Adagio Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.43 | -0.04 |
| 20.99% | 97.20% | |
| P/E | negative | |
| EV/Sales | 0.42 |
3 Analysts have issued a Adagio Therapeutics Inc forecast for earnings per share. The average Adagio Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Adagio Therapeutics Inc...
Current Adagio Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 28 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | May 16 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 26 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Mar 05 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 28 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
May 16 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 26 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Mar 20 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Mar 05 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 24 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Feb 24 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
